Cargando…

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase

Little is known about the impact of pretreatment drug resistance (PDR) on the efficacy of second generation integrase inhibitors. We sequenced pretreatment plasma specimens from the ADVANCE trial (NCT03122262). Our primary outcome was 96-week virologic success, defined as a sustained viral load <...

Descripción completa

Detalles Bibliográficos
Autores principales:	Siedner, Mark J., Moorhouse, Michelle A., Simmons, Bryony, de Oliveira, Tulio, Lessells, Richard, Giandhari, Jennifer, Kemp, Stephen A., Chimukangara, Benjamin, Akpomiemie, Godspower, Serenata, Celicia M., Venter, Willem D. F., Hill, Andrew, Gupta, Ravindra K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708638/ https://www.ncbi.nlm.nih.gov/pubmed/33262331 http://dx.doi.org/10.1038/s41467-020-19801-x

Ejemplares similares

Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa
por: Chandiwana, Nomathemba C., et al.
Publicado: (2021)

Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic
por: Pepperrell, Toby, et al.
Publicado: (2020)

The ADVANCE study: a groundbreaking trial to evaluate a candidate universal antiretroviral regimen
por: Venter, Willem D.F., et al.
Publicado: (2017)

Affordable drug resistance genotyping of HIV-1 reverse transcriptase, protease and integrase genes, for resource limited settings
por: Manyana, Sontaga, et al.
Publicado: (2023)

Is laboratory screening prior to antiretroviral treatment useful in Johannesburg, South Africa? Baseline findings of a clinical trial
por: Venter, Willem D. F., et al.
Publicado: (2017)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

HIV-1 Protease, Reverse Transcriptase, and Integrase Variation
por: Rhee, Soo-Yon, et al.
Publicado: (2016)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Cis-Allosteric Regulation of HIV-1 Reverse Transcriptase by Integrase
por: Masuda, Takao, et al.
Publicado: (2022)

Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022)

Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?
por: Fairlie, Lee, et al.
Publicado: (2019)

Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase
por: Singh, Kamal, et al.
Publicado: (2019)

Non-Nucleoside Reverse Transcriptase Inhibitors Join Forces with Integrase Inhibitors to Combat HIV
por: Himmel, Daniel M., et al.
Publicado: (2020)

Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex
por: Wang, Joy Y., et al.
Publicado: (2021)

Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
por: Winters, Mark A., et al.
Publicado: (2012)

The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance
por: Wainberg, Mark A.
Publicado: (2012)

Coevolutionary Analysis Identifies Protein–Protein Interaction Sites between HIV-1 Reverse Transcriptase and Integrase
por: Hetti Arachchilage, Madara, et al.
Publicado: (2016)

Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial
por: Venter, Willem Daniel Francois, et al.
Publicado: (2019)

Coevolved Multidrug-Resistant HIV-1 Protease and Reverse Transcriptase Influences Integrase Drug Susceptibility and Replication Fitness
por: Martin, Supang A., et al.
Publicado: (2021)

Treatment And Prevention for female Sex workers in South Africa: protocol for the TAPS Demonstration Project
por: Gomez, Gabriela B, et al.
Publicado: (2016)

Basic Quinolinonyl Diketo Acid Derivatives as Inhibitors of HIV Integrase and their Activity against RNase H Function of Reverse Transcriptase
por: Costi, Roberta, et al.
Publicado: (2014)

Flavonol 7-O-Glucoside Herbacitrin Inhibits HIV-1 Replication through Simultaneous Integrase and Reverse Transcriptase Inhibition
por: Áy, Éva, et al.
Publicado: (2019)

HIV-1 Reverse Transcriptase/Integrase Dual Inhibitors: A Review of Recent Advances and Structure-activity Relationship Studies
por: Mahboubi-Rabbani, Mohammad, et al.
Publicado: (2021)

Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa
por: Sokhela, Simiso, et al.
Publicado: (2022)

Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq
por: Dudley, Dawn M, et al.
Publicado: (2014)

Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
por: Tovar Sanchez, Tamara, et al.
Publicado: (2023)

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART
por: Derache, Anne, et al.
Publicado: (2019)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

In Vitro Anti-HIV-1 Reverse Transcriptase and Integrase Properties of Punica granatum L. Leaves, Bark, and Peel Extracts and Their Main Compounds
por: Sanna, Cinzia, et al.
Publicado: (2021)

A Partially Multiplexed HIV Drug Resistance (HIVDR) Assay for Monitoring HIVDR Mutations of the Protease, Reverse-Transcriptase (PRRT), and Integrase (INT)
por: DeVos, Joshua, et al.
Publicado: (2022)

Patterns of Immune Activation in HIV and Non HIV Subjects and Its Relation to Cardiovascular Disease Risk
por: Vos, Alinda G., et al.
Publicado: (2021)

Impact of pretreatment low-abundance HIV-1 drug-resistant variants on virological failure among HIV-1/TB-co-infected individuals
por: Chimukangara, Benjamin, et al.
Publicado: (2020)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

A reverse transcriptase ribozyme
por: Samanta, Biswajit, et al.
Publicado: (2017)

Drug Resistance Mutations Against Protease, Reverse Transcriptase and Integrase Inhibitors in People Living With HIV-1 Receiving Boosted Protease Inhibitors in South Africa
por: Obasa, Adetayo Emmanuel, et al.
Publicado: (2020)

Reverse transcriptase activity in psoriatic lesions: effects of reverse transcriptase inhibitors on keratinocyte proliferation and differentiation
por: Molès, Jean-Pierre, et al.
Publicado: (2009)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention
por: Gupta, Ravindra K, et al.
Publicado: (2013)

Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
por: Moyo, Sikhulile, et al.
Publicado: (2019)

High Resolution analysis of Transmission Dynamics of Sars-Cov-2 in Two Major Hospital Outbreaks in South Africa Leveraging Intrahost Diversity
por: James, San Emmanuel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_erlsd1j7ropm1p2pb9k466i0ij